Data / Research funding / New York / Vizlitics Inc.
Vizlitics Inc.: 4 NIH awards ($4.1M), fiscal years 2021 to 2026
Vizlitics Inc. in Chappaqua, NY is funded under 4 NIH awards ($4.1M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- N1EMHHVX3F35
- State
- New York
Awards
4 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| ONTRIAL: AI-DRIVEN AND EMR INTEGRATED CLINICAL TRIAL RECRUITMENT TOOL USED BY CLINICAL TRIAL AND PROVIDER TEAMS FOR RECRUITMENT OF DIVERSE POPULATIONS. | NIH | National Cancer Institute | 2024 | $2,049,966 | September 16, 2024 | September 15, 2026 | SHEARER, CHAD | reporter.nih.gov |
| VIPCare: Virtual Predictive Care workflow with EHR integrated surveillance for optimalfollow-up care management for Cancer Patients | NIH | National Cancer Institute | 2025 | $1,154,996 | September 1, 2023 | August 31, 2027 | BAGCHI, SUGATO | reporter.nih.gov |
| VIPCare: A cancer patient surveillance platform that runs clinical workflow for identifying, tracking, evaluating and engaging cancer surveillance cases. | NIH | National Cancer Institute | 2023 to 2024 | $461,500 | September 1, 2023 | August 31, 2024 | HENSLEY ALFORD, SHARON | reporter.nih.gov |
| OncoPath: Intelligent Clinical Pathway Decision Support Tool for Pre-Authorization Documentation in Non-Small Cell Lung Cancer Treatment | NIH | National Cancer Institute | 2021 | $398,721 | September 1, 2021 | August 31, 2022 | HENSLEY ALFORD, SHARON | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2025 | 1 | $1,154,996 | 0 | $0 |
| 2024 | 2 | $2,104,966 | 0 | $0 |
| 2023 | 1 | $406,500 | 0 | $0 |
| 2021 | 1 | $398,721 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.393 | November 2, 2026 | Not listed | Same assistance listing 93.393 as 3 awards here |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | PAR-25-095 | NIH | 93.393 | November 6, 2026 | $350,000 | Same assistance listing 93.393 as 3 awards here |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | PAR-25-096 | NIH | 93.393 | November 17, 2026 | $200,000 | Same assistance listing 93.393 as 3 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.393 | November 20, 2026 | Not listed | Same assistance listing 93.393 as 3 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.393 | January 7, 2027 | $375,000 | Same assistance listing 93.393 as 3 awards here |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) | PAR-25-069 | NIH | 93.393 | January 7, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | PAR-25-070 | NIH | 93.393 | January 7, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-25-081 | NIH | 93.393 | January 7, 2027 | $499,999 | Same assistance listing 93.393 as 3 awards here |
| Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | PAR-25-167 | NIH | 93.393 | January 7, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed) | RFA-NS-25-023 | NIH | 93.393 | January 15, 2027 | $350,000 | Same assistance listing 93.393 as 3 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.393 | January 25, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) | RFA-CA-26-010 | NIH | 93.393 | January 25, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed) | RFA-CA-28-013 | NIH | 93.393 | February 9, 2027 | $700,000 | Same assistance listing 93.393 as 3 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.393 | April 5, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.393 | April 5, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed) | PAR-28-057 | NIH | 93.393 | May 25, 2027 | $500,000 | Same assistance listing 93.393 as 3 awards here |
| Implementation and Evaluation of Databases to Examine AIDS | RFA-AI-28-025 | NIH | 93.393 | May 27, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional) | PAR-25-210 | NIH | 93.393 | June 2, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional) | PAR-25-211 | NIH | 93.393 | June 2, 2027 | Not listed | Same assistance listing 93.393 as 3 awards here |
| Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-28-003 | NIH | 93.393 | June 11, 2027 | $600,000 | Same assistance listing 93.393 as 3 awards here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.